Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease.
Soluble guanylate cyclase (sGC) is a key enzyme of the nitric oxide-cyclic guanosine 3',5'-monophosphate (NO-cGMP) signaling pathway, and its pharmacological stimulation has been shown to prevent the development of emphysema and pulmonary vascular remodeling in animal models of chronic obs...
Main Authors: | Tanja Paul, Anna Salazar-Degracia, Victor I Peinado, Olga Tura-Ceide, Isabel Blanco, Esther Barreiro, Joan A Barberà |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5755849?pdf=render |
Similar Items
-
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01) -
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01) -
Activation mechanism of human soluble guanylate cyclase by stimulators and activators
by: Rui Liu, et al.
Published: (2021-09-01) -
Regulation, activation, and deactivation of soluble guanylate cyclase and NO-sensors
by: Petrova, Olga
Published: (2017) -
First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
by: Till Spreemann, et al.
Published: (2017-12-01)